CMAJ • February 13, 2007; 176 (4). doi:10.1503/cmaj.1060144.
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ashworth, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashworth, A. J.
Related Collections
Right arrow Heart failure
Right arrow Drugs: cardiovascular system

Letters

Cardiac risks with COX-2 inhibitors

Andrew J. Ashworth

Davidson's Mains Medical Centre, Edinburgh, UK

Linda Levesque and colleagues' findings concerning the timing of cardiovascular risks in elderly users of cyclooxygenase-2 (COX-2) inhibitors are interesting,1 but they might reflect the superiority of rofecoxib over other agents as an analgesic and anti-inflammatory agent rather than any specific cardiotoxic effect of this drug. The peak in the risk of cardiac events in the second week of treatment with rofecoxib might simply be related to increased activity levels in patients who had previously been in pain and who therefore had probably been less active and had experienced a decline in physical fitness. With a half-life of 24 hours, it takes 6 half-lives (about a week) for rofecoxib to reach steady state and maximal sustained efficacy. The finding that cardiac risk dropped back toward baseline after the second week could be explained by the patients' improved cardiac fitness resulting from a further week of increased physical activity. Perhaps we should be careful about how well we treat long-standing arthritis in those who long to be more active again.

REFERENCE

  1. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006;174(11):1563-9. [Abstract/Free Full Text]



eLetters:

Read all eLetters

Timing of cardiovascular risk with COX-2 inhibitors
Michal R. Pijak
CMAJ, 26 Feb 2007 [Full text]
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ashworth, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashworth, A. J.
Related Collections
Right arrow Heart failure
Right arrow Drugs: cardiovascular system